ADC Injection Composition for Aggregation-Stable Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugate (ADC) formulations face challenges with aggregation and degradation, leading to pharmaceutically undesirable side effects and risks, particularly during storage, which affect efficacy and toxicity.
Innovation Solution
A pharmaceutical composition comprising an antibody-drug conjugate with specific linker-drug molecules conjugated to antibodies targeting HER2, HER3, or EGFR, formulated with buffering agents, stabilizers, and surfactants to enhance stability and minimize aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugate is formulated for targeted drug delivery, then therapeutic potential is improved, but aggregation and degradation occur during storage
Solution Approach 1:
The patent employs buffering agents (e.g., histidine, phosphate), stabilizers (e.g., sucrose, trehalose), and surfactants (e.g., polysorbate 80) as intermediary substances that mediate between the antibody-drug conjugate and the storage environment. These additives prevent aggregation and degradation by forming protective interactions with the ADC molecules, thereby maintaining stability without compromising therapeutic potential.
Solution Approach 2:
The patent optimizes formulation parameters including pH (adjusted to 4.0-7.5 using buffering agents), ionic strength, and concentration of stabilizing agents. By carefully controlling these physical and chemical parameters, the formulation achieves a balance where the ADC remains stable during storage while maintaining its therapeutic efficacy and targeted delivery capability.
2Productivity
If small molecule payloads are conjugated to antibody-drug conjugate, then drug delivery is enhanced, but payloads may detach during storage affecting efficacy and toxicity
Solution Approach 1:
The patent employs preliminary stabilization measures during formulation preparation, where stabilizers and buffering agents are added before storage to prevent payload detachment. This preliminary protective action ensures that the linker-drug connection remains intact throughout storage, maintaining both efficacy and controlled toxicity profiles.
Solution Approach 2:
Stabilizing agents such as sugars and amino acids act as intermediary molecules that form a protective matrix around the antibody-drug conjugate, physically preventing the detachment of small molecule payloads during storage while allowing maintained drug delivery function.
3Stability of the object's composition
If ADC formulation is optimized for stability, then aggregation is reduced, but formulation complexity increases with multiple additives
Solution Approach 1:
The patent selects formulation additives that perform multiple functions simultaneously. For example, buffering agents like histidine serve both as pH controllers and as stabilizing agents that prevent aggregation. Surfactants like polysorbate 80 provide both solubility enhancement and aggregation prevention. This multi-functionality reduces the total number of additives needed while achieving comprehensive stability.
Solution Approach 2:
The patent combines multiple stabilization mechanisms into a unified formulation system where buffering agents, stabilizers, and surfactants work synergistically rather than independently. This merged approach achieves superior aggregation prevention with a coordinated set of additives rather than requiring high concentrations of individual agents, thereby managing formulation complexity.
Data Source
Figure 1~5
Figure 6~10
Figure 11~14
AI summary
A pharmaceutical composition comprising an antibody-drug conjugate, a preparation method therefor and a use thereof. Specifically, provided are a pharmaceutical composition comprising an antibody-drug conjugate represented by formula I, which is an injection, a preparation method therefor, and a use thereof in the preparation for a drug for treating proliferative diseases.